Condition
Primary Biliary Cholangitis
Primary biliary cholangitis is an autoimmune condition in which the immune system attacks the small bile ducts in the liver, so bile builds up and damages the liver. Vitamin D and calcium have the strongest evidence, mainly for bone health, since fat malabsorption can leave levels low and osteoporosis risk is high. For bile flow, one very small study of 12 people found cholestasis went down with TUDCA, but that evidence is limited.
Sources: PMID 9918905
- Supplements studied
- 1
- Graded outcomes
- 1
- Trials
- 4
- People studied
- 258
Evidence by supplement
- Strong
- Moderate
- Limited
- Very limited
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Cholestasis Small Decrease | Improves (the measure goes down) | Small effect | 1 study | 12 people | ||
| Liver Enzymes | Changes; see studies | 4 studies | 258 people | |||
Studies that measured liver enzymes
| ||||||
| High-density lipoprotein (HDL) Small Detriment | Worsens (the measure goes down) | Small effect | 24 people | |||
| Total cholesterol | Improves (the measure goes down) | 24 people | ||||
Key findings
- CholestasisImproves (the measure goes down)
The Primary Biliary Cholangitis Supportive Care protocol
2 primary supplements · 6 supporting supplements
Studies cited
5 studies from PubMed
- A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis.
- Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study.
- Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study.
- Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis
- Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: a multicenter placebo-controlled study